After years of resistance from the United States Patent and Trademark Office (USPTO) toward AI patent applications, the patent outlook for AI-related inventions in 2026 appears to be promising thanks to recent changes at the USPTO under Director John A. Squires.
On Sept. 22, 2025, the USPTO swore in Squires as its 60th director. Since
The GT Tel Aviv team of attorneys is pleased to have received top recognition by the Legally Israel 100 league table. Our team is ranked across 10 areas, in addition to individual attorney recognitions.
The team took first place in Hi-Tech (with 159 Israeli Tech clients advised over the past year), and in Employment (advising
Join GT’s Chair of the Global Patent Prosecution Group Barry Schindler, IP & Technology Shareholder Adam Snukal and Patent Agent Dr. Mark Ruberto for the In-House IP Manager Forum Webinar “IP Issues in Different Technology Areas Leveraging AI and Big Data”.
As more technology platforms and solutions are architected around an artificial
We are pleased to announce that in the recently released ranking by Israeli league table Legally Israel 100, Greenberg Traurig’s Tel Aviv office has been recognized in nine categories, more than any other firm recognized in this year’s rankings. These areas include M&A Volume, M&A Value, Real Estate, Litigation, Employment, IP, Capital Markets, Venture
Greenberg Traurig is extremely proud to represent Redhill Biopharma with the recent announcement of providing an initial update on the compassionate use program with its investigational drug, opaganib, in patients with confirmed SARS-CoV-2 infection (COVID-19) in Israel.
RedHill Biopharma is a longstanding client of GT’s Barry Schindler, Chair of Greenberg Traurig’s Global Patent Prosecution
On January 4, 2019, the United States Patent and Trademark Office (USPTO) released new Patent Examiner Guidance (Guidance) for subject matter eligibility. The updated guidance could benefit any technology patent applicant who has a computer-related invention — from smartphones to artificial intelligence — and who has previously had difficulty acquiring patents under the USPTOʼs procedures